← Leaderboards
John Ramunas
Rejuvenation Technologies, Inc.
$4,466,431
Attributed
$4,466,431
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2020–24$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,466,431 · 5
By mechanism
R44$3,869,030 · 3
R43$324,998 · 1
R41$272,403 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dose”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Beth Baseler · Leidos Biomedical Research, Inc.$52,807,683
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Paula Gonzalez-Maya · Fundacion Inciensa$37,578,679
- Xinhua Li · Nano Terra, Inc.$35,520,438
- Jeffrey Reich · Sparian Biosciences, Inc.$28,575,028
Research focus
DoseTelomeraseProteinsMessenger RnaTelomere ShorteningMouse ModelChromosomesCell DivisionRejuvenationCellsTechnologyLipid NanoparticleTelomereLiver FibrosisStem CellsIntravenousNonhuman PrimateBiologicalFibrosisLengthChronicMedicalSenescenceTranslating
Grant awards (6)
TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis$1,858,106
R44 · FY2024 · AA · contact PI
Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic$1,084,194
R44 · FY2024 · TR · contact PI
Clinically-useful vehicles for in vivo delivery of mRNA to stem and progenitor cells$324,998
R43 · FY2024 · GM · contact PI
TERT mRNA lipid nanoparticles to extend telomeres to treat alcoholic hepatitis$626,743
R44 · FY2023 · AA · contact PI
TERT mRNA lipid nanoparticles to extend telomeres to treat pulmonary fibrosis$299,987
R44 · FY2022 · HL · contact PI
Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA$272,403
R41 · FY2020 · AA · contact PI